Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | La Merie | Competitor Analysis: Interferon

Competitor Analysis: Interferon

The Competitive Intelligence Report Interferon as of November 2008 provides a competitor analysis in the development pipeline of novel recombinant and natural interferon alpha, beta, gamma and of other subtypes for treatment of infectious diseases, cancer and multiple sclerosis, respectively.

Total sales of the major interferon alpha, beta and gamma products in 2007 were in excess of US$ 7.2 bln, the majority (US$ 4.6 bln) attributable to beta interferons for treatment of multiple sclerosis. While manufacturers of 1st generation interferon alpha successfully have converted their interferon alpha sales into those of 2nd generation pegylated products, no second generation interferon beta products are in the clinical stage pipeline of any company. The field of beta interferon is far less crowded than that of interferon alpha, despite a nearly two-fold higher market size. This would offer a great opportunity for biosimilar (biogeneric) versions of 1st generation interferon beta products, but surprisingly clinical stage drug candidates are scarce despite numerous preclinical stage projects. In contrast, a huge number of different 1st generation interferon alpha products are produced and marketed in off-patent countries. Quite a number of new developments of long-acting or oral interferon alpha products are in development and will compete with pegylated interferons of established manufacturers Roche and Schering-Plough.

The report describes the market size of the major type interferon products, provides information on the marketed interferon preparations and includes a compilation of current active projects in research and development of novel interferon products. Competitor projects are listed in a tabular format providing information on:

* Drug Codes,

* Target / Mechanism of Action,

* Class of Compound,

* Company,

* Product Category,

* Indication,

* R&D Stage and

* additional comments with a hyperlink leading to the source of information.

Index

Interferon Sales 2007

Interferon alpha:

* 1st generation IFN alpha-2a

* 1st generation IFN alpha-2a biosmilars and off-patent country products

* 2nd generation IFN alpha-2a

* 2nd generation IFN alpha-2a biosimilars and off-patent country products

* 1st generation IFN alpha-2b

* 1st generation IFN alpha-2b biosimilars and off-patent country products

* 2nd generation IFN alpha-2b

* 2nd generation IFN alpha-2b biosimilars and off-patent country products

* IFN alpha-2b new developments

* Other alpha IFN

* Not specified alpha IFN

Interferon beta:

* 1st generation IFN beta-1a

* 1st generation IFN beta-1a biosimilars and off-patent country products

* 1st generation IFN beta-1b

* 1st generation IFN beta-1b biosimilars and off-patent country products

* Other beta IFN

* Not specified beta IFN

Interferon gamma

Other Interferons

Interferons delivered by DNA

Interferons as part of Vaccines

About La Merie

Corporate Interferon Product Portfolio and R&D Pipelines:

* Abraxis Bioscience

* Advanced Protein Technologies (APTECH)

* Aegis Therapeutics

* Alfa Wassermann

* Alios BioPharma

* Amarillo Biosciences

* Ambrx

* Amega Biotech

* Anhui Anke Biotechnology

* Asterion

* Asubio Pharma

* Axxo

* Barofold

* Bayer Schering Pharma & Berlex

* Bio Sidus

* Bio-Manguinhos

* Biogen Idec

* BioGeneric Pharma

* Biolex

* Bioorganic Research and Services (Bionaturis)

* Biopartners (Bioton)

* BioSante Pharmaceuticals

* Bolder BioTechnology

* Cinnagen

* CJ Corporation

* Daiichi Sankyo

* Dainippon Sumitomo Pharma

* Digna Biotech

* Dong-A Pharmaceuticals

* Egis Pharmaceuticals & Trigon Biotechnology

* Flamel Technologies

* Genexine

* GenOdyssee

* Green Cross

* HanAll Pharmaceutical

* Hanmi Pharmaceutical

* Heber Biotec

* Helix BioPharma

* Human Genome Sciences

* Ichor Medical Systems

* InSight Biopharmaceuticals

* Intarcia Therapeutics

* Intas Pharmaceuticals

* InterMune

* Intranasal Technology

* Kee Pharma

* Laboratorios Cryopharma

* Lipoxen

* LG Life Sciences

* Merck Serono

* Mochida Pharmaceutical Co.

* Modigene

* MolMed

* Nanogen Biopharmaceuticals

* Nautilus Biotech

* Novartis

* Otsuka Pharmaceutical Co.

* PBL Therapeutics

* Phage Biotechnology

* PharmaEssentia

* Probiomed

* Proxima Concepts (Kancer Ltd.)

* Reliance Life Sciences & Reliance GeneMedix

* Rhein-Minapharm Biogenetics

* RioTech Pharma

* Roche

* Schering-Plough

* Shantha Biotechnics

* Shenyang Sunshine Pharmaceutical Co

* Shenzhen Kexing Biotech

* Shire

* Sudershan Biotech

* Swedish Orphan

* Synairgen

* Teva Pharmaceutical Industries (CoGenesys & Sicor Biotech)

* Therapeutic Proteins Ltd.

* Three Rivers Pharmaceuticals

* Tinajin Hualida Biotechnology

* Toray

* Transgene

* Transgene Biotek

* USV Ltd (India)

* Vakzine Projekt Management

* Virax Holdings

* Wockhardt

* Zenotech Laboratories

* Zymogenetics

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Pages: 90

Release Date: November of 2008

Format: PDF

Product Code: LMCA0047

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions